PODD vs ZTS: fair value comparison
Insulet Corporation and Zoetis Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PODD currently sits closer to the top of our discount ranking. PODD carries the stronger quality grade.
| PODD | ZTS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $145.13 | $77.34 |
| 12-month range | $148.13–$344.92 | $77.10–$152.88 |
| Sector rank | #4 of 113 Healthcare | #5 of 113 Healthcare |
| Quality grade | A | C |
| Momentum grade | — | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: PODD fair value analysis · ZTS fair value analysis